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Abstract
Control of human African sleeping sickness, caused by subspecies of the protozoan parasite Trypanosoma brucei, is based
on preventing transmission by elimination of the tsetse vector and by active diagnostic screening and treatment of infected
patients. To identify trypanosome proteins that have potential as biomarkers for detection and monitoring of African
sleeping sickness, we have used a ‘deep-mining’’ proteomics approach to identify trypanosome proteins in human plasma.
Abundant human plasma proteins were removed by immunodepletion. Depleted plasma samples were then digested to
peptides with trypsin, fractionated by basic reversed phase and each fraction analyzed by liquid chromatography-tandem
mass spectrometry (LC-MS/MS). This sample processing and analysis method enabled identification of low levels of
trypanosome proteins in pooled plasma from late stage sleeping sickness patients infected with Trypanosoma brucei
rhodesiense. A total of 254 trypanosome proteins were confidently identified. Many of the parasite proteins identified were
of unknown function, although metabolic enzymes, chaperones, proteases and ubiquitin-related/acting proteins were
found. This approach to the identification of conserved, soluble trypanosome proteins in human plasma offers a possible
route to improved disease diagnosis and monitoring, since these molecules are potential biomarkers for the development
of a new generation of antigen-detection assays. The combined immuno-depletion/mass spectrometric approach can be
applied to a variety of infectious diseases for unbiased biomarker identification.
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Introduction
Several methods are currently used to diagnose human African
trypanosomiasis (HAT), also known as African sleeping sickness.
These include detection of anti-trypanosome antibodies [1,2],
amplification of DNA sequences [3,4] and direct observation of
parasites by microscopic examination of patient blood or
cerebrospinal fluid (CSF), usually preceded by parasite enrichment
techniques [5]. Although each of these methods has problems that
hinder reliable, high throughput and cost effective disease
diagnosis, together, they do help disease control efforts [6].
Currently, the only way to definitively diagnose HAT in the
field is to microscopically observe trypanosomes in the blood (early
stage disease) and in the CSF (late stage disease). Using parasite
enrichment techniques, the current limit of microscopic detection
is ,100 trypanosomes/mL of blood [5], thus between parasitemic
waves, parasite numbers lower than this make microscopic
detection unreliable. Due to low sensitivity and low throughput,
microscopic diagnosis is only used to confirm suspected infections
and is not an effective tool for mass screening campaigns.
The card agglutination test for trypanosomiasis (CATT, [1]) is
the most commonly used assay for mass screening in the field as it
is relatively easily performed and requires minimal instrumenta-
tion [5]. It is not ideal, since it is only useful for detecting
antibodies generated during infections with Trypanosoma brucei
gambiense that often, but not always, express a particular, defined
variant surface glycoprotein (VSG) during waves of parasitemias.
Infections with T. b. gambiense parasites in west and central Africa
may be missed if that VSG type is not expressed. In addition, the
CATT is not useful for detecting infections with T. b. rhodesiense,
parasites that cause acute infections in eastern and southern
Africa.
Although antibody detection is often used as a first line
diagnostic test for many infectious diseases, antibodies often persist
in the bloodstream after a person has been cured. Therefore
antibody detection is usually not useful for discriminating between
current and past infections. For this reason, and the fact that no
antibody detection tests for T. b. rhodesiense infections are available,
diagnostic assays for African sleeping sickness based on parasite
antigen detection are deemed to be more desirable. Previous
studies have shown that trypanosome antigens are detectable by
immunoassay in the sera of infected cattle [7,8,9], rodents [10],
vervet monkeys [11] and humans [12,13]. Previous work from our
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lab showed that trypanosome antigens (with both T. b. gambiense
and T. b. rhodesiense infections) appeared in the blood soon after
infection [10,11] were present at detectable levels throughout the
infection (regardless of the oscillating parasite population associ-
ated with antigenic variation) and were reduced to undetectable
levels within weeks of the infections being cured [12,13]. Despite
reports of antigen detection assays for animal and human
trypanosomiasis [7,8,9,10,11,12,13,14,15] only one (for animal
trypanosomiasis; [9]) described the identity of the analyte. No
reliable antigen detection tests have been developed and imple-
mented for wide-scale use in the field. The collective data suggest
that antigen detection assays have potential for diagnosis and
monitoring of HAT although it is clear that more effort is required
to identify parasite antigens of greatest utility. Several strategies
towards antigen identification have been publically suggested
[16,17]. However these are based on examination of the parasites
themselves and are not aimed directly at identification of the most
relevant molecules that are found circulating in a patient’s
bloodstream. Identification of parasite proteins in the blood or
plasma of an infected host is the most direct approach for
discovery of candidate biomarkers for diagnosis and monitoring of
trypanosomiasis. This strategy, however, is made technically
difficult by the high abundance of human plasma proteins
[18,19], almost certainly explaining the failure over the past 30
years to identify trypanosome antigens in the blood of infected
patients.
Here we describe a ‘‘deep mining’’ protein discovery method-
ology using liquid chromatography-tandem mass spectrometry
(LC-MS/MS) to identify low abundance trypanosome proteins in
human plasma. The approach used involved immunodepletion of
the most abundant human plasma proteins, protease digestion of
remaining proteins, extensive fractionation of the peptides and
their identification using a highly sensitive Q Exactive Orbitrap
mass spectrometer (Thermo Scientific). The peptides were used to
identify their parent proteins, both human and trypanosome. To
test this approach, we used plasma from. T. b. rhodesiense-infected
patients with late stage sleeping sickness, since this parasite can
cause acute infections with high levels of parasitemia, thus
potentially releasing detectable levels of parasite proteins into the
blood. Trypanosome proteins identified by this immunodepletion-
proteomic technique are candidate biomarkers and ideal targets
for developing new immunoassays assays for either initial diagnosis
or for monitoring HAT. Although our initial study was performed
with plasma from late-stage patients infected with T. b. rhodesiense,
the results indicate that the generic approach and methods could
be applied to T. b. gambiense infections, to animals infected with
other trypanosome species and to many other infectious diseases.
Materials and Methods
Ethics Statement
Ethical clearance for the project ‘‘Biomarker discovery for
staging human African trypanosomiasis patients’’ involving human
plasma and CSF from sleeping sickness patients and control
subjects was approved by the Ethical Review Board of the Vector
Control Division of the Ministry of Health, Kampala, Uganda. All
sleeping sickness patients gave written informed consent before
enrolment and all had the option of withdrawing from the studies
at any time. The Human Research Ethics Board of the University
of Victoria (protocol number: 11–531) and the Massachusetts
Institute of Technology’s Committee on the Use of Humans as
Experimental Subjects, one of the Broad Institute’s institutional
review boards of record, also approved the studies.
Trypanosomes and Cell Culture
T. congolense IL3000 [20], T. b. brucei 427.01 [21], T. b. rhodesiense
ViTat 1.1 [22] and T. b. gambiense U2 [22] were originally obtained
as bloodstream form (BSF) stabilates from the International
Livestock Research Institute, Nairobi, Kenya. Procyclic culture
forms (PCF) of trypanosomes were derived from their correspond-
ing BSF by transformation at 27uC [23] and were maintained at
27uC in a modified minimal essential medium containing 10%
fetal bovine serum [20].
Production of Anti-trypanosome Antibodies
As probes for parasite antigens, anti-trypanosome antibodies
were generated by immunizing rabbits with lysates of T. b.
rhodesiense PCF. The PCF life cycle stage was chosen as the
immunogen in order to generate antibodies against conserved
cellular proteins and to avoid reactivity with the immunodominant
VSG molecules of BSF trypanosomes. Rabbit antisera were made
by immunizing two New Zealand White rabbits (contracted to
Epitomics Inc., Burlingame CA) with T. b. rhodesiense ViTat1.1
PCF lysate. In brief, rabbits were bled to obtain pre-immunization
sera and after one day of rest were immunized with trypanosome
lysate prepared by sonicating 26107 parasites/mL in PBS
containing 1x protease inhibitor cocktail V (Cat. No. 539137,
Calbiochem). An extended immunization procedure over a total of
78 days, involving 4 injections (1 priming dose of immunogen in
Freund’s Complete Adjuvant and 3 boosts with immunogen in
Freund’s Incomplete Adjuvant) of immunogen preparation was
performed. Blood was collected and sera prepared one week after
the final boost and stored at 220uC until used.
Table 1. Summary of patient information.
Sample Code Sex Age Date of Isolation Infection Status Stage Leukocyte count Plasma CSF
LWO24A F 55 14/01/2008 T. b. rhodesiense Late 7 Yes Yes
LWO24B F ‘‘’’ 26/03/2008 Drug cured NA NA Yes No
LWO25A M 12 17/01/2008 T. b. rhodesiense Late 13 Yes Yes
LWO25B M ‘‘’’ 10/03/2008 Drug cured NA NA Yes No
LWO31A M 54 20/02/2008 T. b. rhodesiense Late 86 Yes Yes
LWO31B M ‘‘’’ 13/04/2008 Drug cured NA NA Yes No
Plasma and CSF were collected from T. b. rhodesiense-infected patients confirmed to have late stage human African trypanosomiasis at Lwala Hospital in central Uganda.
doi:10.1371/journal.pone.0071463.t001
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Titration of Anti-trypanosome Antibodies
Indirect enzyme linked immunosorbent assays (ELISA) were
performed essentially as previously described [24] with the rabbit
anti-T. b. rhodesiense PCF antiserum used as the source of primary
antibodies. The antigens used to coat the ELISA plate wells were
PCF lysates (56105 cells per well of T. b. rhodesiense ViTat 1.1, T. b.
gambiense U2, T. congolense IL3000 and T. b. brucei 427.01) and
diluted human plasmas. Small amounts of plasma samples from
patients were used (1 mL plasma diluted in 99 mL of water) to coat
the ELISA plate wells in order to avoid overloading the ELISA
wells with protein which could either mask low abundance parasite
proteins or lead to erroneously high signals resulting from non-
specific protein-protein interactions. The secondary antibody used
was a 1:4000 dilution of goat anti-rabbit IgG (H+L) – AP (Cat. No.
075–1516, Kirkegaard-Perry Laboratories, Gaithersburg MD).
Collection of Plasma and CSF from Human African
Trypanosomiasis Patients
Plasma and CSF were collected from sleeping sickness patients
received at the Lwala Hospital, Kaberamaido District, Uganda in
Figure 1. ELISA detection of trypanosome antigens in plasma from T. b. rhodesiense-infected patients with late-stage human African
trypanosomisis. All samples were tested in duplicate and the average response is shown. Error bars represent 1 standard deviation.
doi:10.1371/journal.pone.0071463.g001
Table 2. Variant Surface Glycoproteins (VSGs) discovered in pooled plasma from T. b. rhodesiense-infected patients confirmed to
have late-stage human African trypanosomiasis.
Molar Intensity Accession No. No. of Peptides % Sequence Coverage Protein Name
3.49E+09 Tb927.5.291b 2 5.1 variant surface glycoprotein, putative
9.80E+08 Tb09.244.0200 3 5.4 variant surface glycoprotein, putative
9.10E+08 Tb10.v4.0152 2 3.5 variant surface glycoprotein, putative
5.20E+08 Tb11.57.0012 2 5.3 variant surface glycoprotein pseudogene, putative
4.97E+08 Tb927.5.5210 2 6.6 variant surface glycoprotein, putative
4.46E+08 Tb11.30.0008 2 4 variant surface glycoprotein pseudogene, putative
2.58E+08 Tb927.5.4670 5 14.4 variant surface glycoprotein, putative
2.27E+08 Tb927.4.5410 2 5.3 variant surface glycoprotein, putative
2.11E+08 Tb10.v4.0058 2 5.2 variant surface glycoprotein, putative
1.71E+08 Tb05.5K5.530 2 5.6 variant surface glycoprotein, putative
1.37E+08 Tb05.5K5.320 2 3.8 variant surface glycoprotein, putative
6.85E+07 Tb10.v4.0134 2 4.8 variant surface glycoprotein, putative
doi:10.1371/journal.pone.0071463.t002
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2008. Patients were first identified by passive surveillance by the
clinician on duty who referred them for parasitological analysis in
the hospital laboratory. First, wet blood smears were examined for
trypanosomes by light microscopy. For detection of low level
parasitemias, the hematocrit centrifugation technique was used
[25]. Patients with detectable bloodstream parasitemias were
staged after double centrifugation of CSF and microscopic
counting of trypanosomes and white blood cells. Blood samples
were collected and plasma prepared using Vacutainer tubes
(K2EDTA; lavender; Becton Dickinson). Following melarsoprol
treatment and apparent cure, a second plasma sample was also
collected from each patient. All samples were assigned a patient
code (e.g. LWO24). An ‘‘A’’ or ‘‘B’’ following the patient code
indicates that the sample was collected either while the patient was
infected or after drug cure, respectively.
All plasmas and CSF samples centrifuged and then stored in
liquid nitrogen on site at the Lwala Hospital prior to transpor-
tation to Makerere University, Kampala, followed by shipment on
dry ice to the University of Victoria. A descriptive summary of the
HAT samples is shown in Table 1.
Immunodepletion and Protease Digestion of Plasma
from Sleeping Sickness Patients
Plasma samples from three confirmed late-stage HAT patients
infected with T. b. rhodesiense were pooled to achieve a total volume
of 500 mL. The protein concentration in the pooled plasma sample
was determined by bicinchoninic acid assay (Cat. No. 23225,
Pierce, Rockford, USA) to be 59 mg/ml. The sample was depleted
of high and medium abundance human proteins using two
immunoaffinity columns in a serial configuration: a Human IgY14
LC20 column (for removal of the top 14 most abundant proteins)
and a Human Supermix LC10 column (SEP000-1KT SEPPRO
Depletion Column; Sigma-Aldrich St. Lois, MO). The latter resin
has been reported to remove at least 155 proteins, 38% of the
plasma proteome in protein number and 94% of plasma protein in
mass [26]. The depleted plasma was concentrated to 400 ml using
a 15 mL, 3 kDa concentrator (Cat. No. UFC900324 Amicon,
Billerica, USA) by centrifuging for 60 minutes at 40006g. The
concentrated plasma was then buffer exchanged and denatured
with 12 mL of a 6 M urea/50 mM ammonium bicarbonate
solution by centrifuging for 2 hours at 40006g until the final
volume of the concentrate reached 400 ml. The protein yield of the
depleted, concentrated plasma was determined by a Coomassie
Plus (Bradford) Protein Assay (Cat. No. 23236 Thermo Scientific,
USA).
Proteins in the denatured sample were first treated with Lys-C
(Cat. No. 129-02541, Wako, Richmond, VA) followed by digestion
with sequencing grade modified trypsin (Cat. No. V5280,
Promega, Madison, WI) according to an in-solution digestion
protocol. In brief, the pooled, protein depleted sample was first
incubated for 30 minutes at 37uC in 20 mM dithiothreitol
followed by addition of iodoacetamide to a final concentration
of 50 mM followed by incubation for an additional 30 minutes at
room temperature in the dark. The urea was diluted to 2 M with
Table 3. Chaperones and protein isomerases identified in pooled plasma from T. b. rhodesiense-infected patients with
parasitologically confirmed late stage human African trypanosomiasis.
Molar
Intensity Accession No.
No. of
Peptides
% Sequence
Coverage Protein Name
3.08E+10 Tb927.7.710 4 6.7 heat shock 70 kDa protein, putative
2.65E+10 Tb927.6.3740 4 8.6 heat shock protein 70, mitochondrial precursor, putative
1.73E+10 Tb10.61.1940 2 2.2 chaperone protein DNAJ, putative
1.52E+10 Tb09.211.1350 2 6.7 peptidyl-prolyl cis-trans isomerase, putative
8.33E+09 Tb11.01.3110 33 47.9 heat shock protein 70
6.10E+09 Tb927.7.4590 2 2.1 chaperone protein DNAJ, putative
4.96E+09 Tb927.7.4770 8 64.7 peptidyl-prolyl cis-trans isomerase, putative
4.79E+09 Tb10.26.1080 29 40.3 heat shock protein 83
4.22E+09 Tb927.7.1320 6 77 1010 kDa heat shock protein, putative
3.89E+09 Tb11.03.0250 10 74 cyclophilin a
2.05E+09 Tb927.7.5790 4 25.1 protein disulfide isomerase, putative
1.81E+09 Tb11.02.5450 11 23.5 glucose-regulated protein 78, putative
1.69E+09 Tb10.6k15.2290 10 22.5 protein disulfide isomerise
1.49E+09 Tb927.8.7410 17 50.6 calreticulin, putative
1.49E+09 Tb927.4.5010 16 45 calreticulin, putative
1.12E+09 Tb10.61.0180 9 38.5 peptidylprolyl isomerase-like protein, putative
2.86E+08 Tb927.7.1300 13 39.5 protein disulfide isomerase, putative
2.47E+08 Tb10.70.0280 10 26.3 heat shock protein 60 chaperonin, mitochondrial precursor
2.07E+08 Tb927.8.690 2 26.9 peptidyl-prolyl cis-trans isomerase, putative
1.39E+08 Tb927.5.2940 10 20.9 stress-induced protein sti1, putative
9.19E+07 Tb10.389.0880 9 17 heat shock protein, putative
8.05E+07 Tb927.3.5340 2 6.2 heat shock cognate 70 - interacting protein, putative
6.35E+07 Tb11.02.0250 8 12.2 heat shock protein 84, putative
doi:10.1371/journal.pone.0071463.t003
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water prior to a 4 hour digestion with Lys-C at 1:50 (w/w) enzyme
to substrate ratio at 37uC. The urea was further diluted with water
to 0.6 M and the pH was adjusted to 8.0 with 1 M Tris base prior
to trypsin addition (1:50 enzyme to substrate ratio) and incubation
overnight at 37uC. The reaction was stopped by addition of formic
acid (FA) to a final concentration of 1% and the solution was
desalted with a 1 cc (30 mg) Oasis HLB reverse phase cartridge
(Cat. No. WAT054955, Waters, Milford, USA) conditioned with
36500 mL acetonitrile (ACN), followed by 46500 mL 0.1% FA.
Samples were loaded onto the cartridges and washed with
36500 mL 0.1% FA. Desalted peptides were eluted by 2
applications of 500 mL of 80% ACN/0.1% FA. Eluates were
Table 4. Proteases and ubiquitin proteins discovered in pooled plasma from T. b. rhodesiense-infected patients with
parasitologically confirmed late stage human African trypanosomiasis.
Molar Intensity Accession No. No. of Peptides % Sequence Coverage Protein Name
5.43E+10 Tb11.01.1680 12 9.4 polyubiquitin, putative
2.90E+09 Tb09.211.3610 5 3.9 ubiquitin-activating enzyme E1, putative
2.70E+09 Tb09.211.0050 5 23.3 ubiquitin-conjugating enzyme E2, putative
2.08E+09 Tb927.5.1000 5 68.9 ubiquitin-conjugating enzyme E2, putative
1.68E+09 Tb927.2.3030 2 1.8 ATP-dependent Clp protease subunit, putative
1.48E+09 Tb11.47.0035 2 0.4 calpain-like cysteine peptidase, putative
1.44E+09 Tb11.02.0070 3 9.7 aminopeptidase NPEPL1
9.67E+08 Tb11.02.4440 24 70.8 aminopeptidase, putative
7.17E+08 Tb927.7.4060 6 60 calpain-like cysteine peptidase, putative
6.30E+08 Tb11.02.0815 2 18.1 ubiquitin-conjugating enzyme, putative
3.38E+08 Tb10.6k15.2520 34 56.3 prolyl oligopeptidase, putative
1.25E+08 Tb10.6k15.0580 2 4.6 RPT6 proteasome regulatory ATPase subunit 6
9.93E+07 Tb10.6k15.3800 3 3.5 dipeptidyl-peptidase 8-like serine peptidase
9.80E+07 Tb10.70.7080 2 10.3 serine carboxypeptidase III precursor, putative
8.25E+07 Tb927.6.2150 2 4 cell division cycle protein 16, putative
7.73E+07 Tb927.7.190 4 6.4 oligopeptidase A, putative
5.77E+07 Tb11.02.0100 3 8.1 carboxypeptidase, putative
4.66E+07 Tb10.61.1870 2 6.2 aminopeptidase, putative
doi:10.1371/journal.pone.0071463.t004
Table 5. Most abundant* trypanosome proteins found in pooled plasma from T. b. rhodesiense-infected patients with
parasitologically confirmed late-stage human African trypanosomiasis.
Molar
Intensity Accession No.
No. of
Peptides
% Sequence
Coverage Protein Name
5.43E+10 Tb11.01.1680 12 9.4 polyubiquitin, putative
3.08E+10 Tb927.7.710 4 6.7 heat shock 70 kDa protein, putative
2.65E+10 Tb927.6.3740 4 8.6 heat shock 70 kDa protein, mitochondrial precursor, putative
2.13E+10 Tb927.2.1170 2 2.2 retrotransposon hot spot protein, putative
1.73E+10 Tb10.61.1940 2 2.2 chaperone protein DNAJ, putative
1.63E+10 Tb927.8.5600 3 16.2 transaldolase, putative
1.52E+10 Tb09.211.1350 2 6.7 peptidyl-prolyl cis-trans isomerase, putative
1.42E+10 Tb11.02.3210 11 57.2 triosephosphate isomerase
1.37E+10 Tb11.01.4621 13 61.7 calmodulin
1.11E+10 Tb10.6k15.3410 2 1.6 pre-mRNA splicing factor ATP-dependent RNA helicase, putative
9.30E+09 Tb927.4.5340 2 2.2 hypothetical protein, conserved
9.27E+09 Tb927.8.3250 3 0.5 dynein heavy chain, putative
9.20E+09 Tb10.70.4880 2 3.4 eukaryotic translation initiation factor 5, putative
8.73E+09 Tb927.5.2090 3 1.7 kinesin, putative
8.33E+09 Tb11.01.3110 33 47.9 heat shock protein 70
*Abundant proteins were determined by calculating molar intensities as described in Materials and Methods.
doi:10.1371/journal.pone.0071463.t005
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frozen, dried via vacuum centrifugation and stored at280uC prior
to peptide fractionation.
Mass Spectrometric Analysis of Peptides from HAT
Plasma
Basic (pH 10) reverse phase high-performance liquid chroma-
tography (HPLC) was used to fractionate peptides from all 100 mg
of the original digested protein sample using a narrow-bore
2.16150 mm capillary reverse phase column (Agilent: ZORBAX)
packed with 3.5 mm beads and coupled to an Agilent 1100 HPLC
system. The mobile phases were as follows: mobile phase A
(20 mM ammonium formate, 2% ACN, pH 10) and mobile phase
B (90% ACN, 10% 20 mM ammonium formate, pH 10). The
gradient was 0–5 min 0% solvent B, 5–55 min 50% solvent B, 55–
61 min 100% solvent B, 61–80 min 0% solvent B at a constant
flow rate of 0.2 mL/min. A total of 30 fractions were collected
over 0–80 minutes. The fractions were frozen at 280uC and dried
before LC-MS/MS analysis.
The peptides samples in each of the 30 fractions were
resuspended in 8 mL of 3% ACN/0.5% FA before analysis using
a Q Exactive mass spectrometer coupled to an EASY-nLC 1000
UHPLC (Thermo Scientific). A PicoFrit column (New Objective,
Woburn, MA), with an inner diameter of 75 mm and packed with
20 cm of ReproSil-Pur C18 1.9 mm particles, was directly
interfaced to the Q Exactive instrument equipped with a custom
nano-electrospray ionization source. Two mg of the peptide
mixture from each of the 30 fractions were injected and separated
by a 180 minute gradient from 5–60% solvent B. MS/MS analysis
settings for protein identification were as follows: one precursor
MS scan at 70,000 resolution in profile mode was followed by
data-dependent scans of the top 12 most abundant ions at low-
resolution (17,500) in profile mode. Dynamic exclusion was
enabled for a duration of 20 seconds. MS/MS spectra were
collected with a normalized collision energy of 28 and an isolation
width of 2.5 m/z. The extensive peptide fractionation coupled
with in depth MS analysis (instrument time was 90 hours) allowed
detection and identification of very low levels of peptides.
Data Analysis
All MS data were processed using Agilent Spectrum Mill MS
Proteomics Workbench (Agilent Technologies, Palo Alto, USA)
Rev B.04.00.120. MS/MS spectra were searched against an
amalgamated human protein database (UNIPROT) and a T. b.
brucei protein database: (http://phenyx.proteomics.washington.
edu/FASTAcreator/index.cgi). Search parameters were set to:
parent mass tolerance of 20 ppm, fragment mass tolerance of
30 ppm, a maximum of two missed cleavages and carbamido-
methylation and oxidized methionine/pyroglutamic acid as fixed
and variable modifications, respectively. Database matches for
individual spectra were auto-validated according to user-defined
scoring thresholds for both peptides (false discovery rate (FDR)
#1.2%) and proteins (minimum protein score of 20) in a two-step
process. In calculating scores at the protein level and reporting the
identified proteins, redundancy was addressed in the following
manner: the protein score is the sum of the scores of distinct
peptides. A distinct peptide is the single highest scoring instance of
a peptide detected using a MS/MS spectrum. MS/MS spectra for
a particular peptide may have been recorded multiple times (i.e. as
different precursor charge states, isolated from adjacent reverse
phase fractions, oxidation of Methionine) but are still counted as a
single distinct peptide. In Spectrum Mill, FDRs are calculated at 3
different levels: spectrum, distinct peptide and distinct protein.
Peptide FDRs are calculated in Spectrum Mill using essentially the
same pseudo-reversal strategy evaluated by Elias et al. [27] and
shown to perform the same as concatenation. A false distinct
protein identification occurs when all of the relevant peptides,
which group together to constitute a distinct protein, have a delta
Forward Reverse Score #0. Spectrum Mill also performs protein
grouping using the methods described by Nesvizhskii and
Aebersold [28]. Briefly, when a peptide sequence, (.8 residues
long) is contained in multiple protein entries in the protein
database, the proteins are grouped together and the highest
scoring one and its accession number are reported. In some cases
when the protein sequences are grouped in this manner there are
distinct peptides which uniquely represent a lower scoring member
of the group (isoforms and family members). Each of these
instances spawns a subgroup and multiple subgroups are reported
and counted towards the total number of proteins.
Table 6. List of human plasma proteins with mass spectrometric molar intensities similar to those from the most abundant
trypanosome proteins found in plasma from sleeping sickness patients.
Molar Intensity Accession No. No. of Peptides % Sequence Coverage Concentration (mg/ml)* Protein Name
5.01E+10 P22352 15 58.8 19.0 glutathione peroxidase 3
4.17E+10 P18428 19 38 5.0 lipopolysaccharide-binding protein
3.93E+10 P25311 28 71.4 45.0 zinc-alpha-2-glycoprotein
3.56E+10 P36955 34 64.8 5.0 pigment epithelium-derived factor
2.48E+10 P07225 33 51.7 25.0 vitamin K-dependent protein S
1.69E+10 P29622 31 67.6 14.0 kallistatin
1.53E+10 P04278 25 80 6.5 sex hormone-binding globulin
1.38E+10 P03951 40 73.4 5.0 coagulation factor XI
1.30E+10 Q96IY4 22 57.4 9.5 carboxypeptidase B2
1.18E+10 P23142 29 51.3 40.0 fibulin-1
9.18E+09 P17936 17 58.4 5.0 insulin-like growth factor-binding protein 3
9.01E+09 P04275 142 61 15.0 von Willebrand factor
*Protein concentrations were retrieved from reference [19]. Human proteins reported to be depleted by the LC20 IgY14 and Supermix LC10 columns [26] have been
omitted from this table.
doi:10.1371/journal.pone.0071463.t006
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The sum of the precursor-ion signal intensities of all peptides
derived from each protein was used as an approximation of that
protein’s expression level. The peak area for the extracted ion
chromatogram of each precursor ion in the intervening high-
resolution MS scans of the data-dependent LC-MS/MS runs was
calculated automatically by the Spectrum Mill software using
narrow windows around each individual member of the isotope
cluster. Peak widths in both the time and m/z domains were
dynamically determined based on MS scan resolution, precursor
charge and m/z subject to quality metrics on the relative
distribution of the peaks in the isotope cluster vs theoretical. For
a given protein the ratio of the total protein intensity to total
unique peptides can be deemed the ‘‘molar intensity’’ of that
protein. Therefore, a ranking of the protein molar intensity from
large to small values should, within an order of magnitude, rank
the abundance of the proteins within the given sample.
Results and Discussion
Characterization of Plasma from HAT Patients
To recapitulate previous literature reports, and to gain
confidence that trypanosome antigens were present prior to
undertaking our extensive MS analysis, plasma samples from HAT
patients were examined for the presence of conserved, trypano-
some antigens by indirect ELISA using polyclonal antiserum
against T. b. rhodesiense PCF as a probe. The anti-trypanosome
antibodies were first characterized by immunoblotting and ELISA
and reacted in both assays with antigens in lysates of the
immunizing T. b. rhodesiense PCF and in lysates of T. congolense, T.
b. brucei, and T. b. gambiense (data not shown). The results of the
ELISA performed on human plasma are shown in Figure 1. Two
patients (LWO24 and LWO31) had readily detectable trypano-
some antigens in their plasmas that were recognized by the anti-
PCF antiserum whereas one patient (LW025) did not. The
antigens were not detected in plasmas taken after drug cure and in
plasma from a normal (uninfected) control. Trypanosome antigens
were also detected in CSF of patient LW024 (data not shown).
Since the antigens detected by the anti-T. b. rhodesiense PCF
antiserum may only represent a subset of the antigens present in
the trypanosome infected plasmas, we chose to pool the samples
from all three patients prior to the immunodepletion-MS
approach to be used in the current study. These three patients
provided a good cross section of the patient population. One
patient (LWO24) was a middle aged female. Of the two males, one
was middle aged (LWO25) and the other was in his teens
(LWO31). Despite the plasmas showing variations in antigen levels
by immunoassay with the polyclonal anti-PCF antibodies used, all
three patients were parasitologically confirmed to have late stage
African sleeping sickness. The polyclonal antiserum was only used
in ELISA to generally assess the presence of trypanosome antigens
(described in several previous publications) in the plasma samples
and there is no guarantee that the antigens identified by our MS
analysis are the same as those detected by immunoassay.
Identification of Trypanosome Proteins in Human Plasma
The pooled plasma sample was first immunodepleted of high-
and medium-abundance human proteins to allow detection of the
remaining low-abundance proteins, hopefully including those from
trypanosomes. One hundred mg of total protein (from an initial
29.5 mg in the 500 mL of pooled plasma) remained after protein
depletion and concentration, representing 0.34% of the initial
protein content. After protein digestion to tryptic peptides,
fractionation into 30 basic reverse phase fractions and analysis of
each fraction by LC-MS/MS, 254 trypanosome proteins were
confidently identified (i.e. with at least 2 contributing peptides).
The results are shown in the Supporting Information File
(Appendix S1). An additional 570 trypanosome proteins were
identified based on detection and sequencing of single unique
peptides, bringing the total number of identified trypanosome
proteins to 824. The protein identifications made on the basis of
single peptides may still be relevant but the identifications are
considered to be less reliable than those identifications made on
the basis of multiple observed peptides. Nevertheless, the single
peptides represent non-human sequences and map to trypano-
some proteins thus are deemed to be of parasite origin. It is
possible that some trypanosome proteins could have been removed
inadvertently by off-target binding during the immunodepletion
step [26] although clearly many parasite proteins remained at high
enough levels for their positive identification.
In addition to the trypanosome proteins, 4326 normal human
proteins were also confidently identified (based on two peptides)
and a further 1843 human proteins were possibly correctly
identified (based on one peptide), demonstrating that the
combined depletion-MS method was extremely effective in
identifying a large variety of low abundance proteins in plasma.
The sensitivity achieved with the combined methods for detection
of trypanosome proteins suggests that parasite proteins may be
detected even with much lower levels of parasitemia, for example
at early stages of infection with T. b. rhodesiense or with the usually
more chronic infections with T. b. gambiense.
A complete list of all of the proteins identified (both human and
trypanosome) can be found in the Supporting Information as an
Excel file (Appendix S1). The single peptide data have also been
included in Appendix S1 but will not be discussed further in the
text of this manuscript.
The large number of trypanosome proteins discovered in the
plasma from the HAT patients can be attributed in part to our
choice of plasmas from patients with late-stage T. b. rhodesiense
infections, part of our strategy to ensure that parasite proteins were
present for this proof of concept approach. Although specific
durations of infection prior to hospitalization for these patients
were unknown it has been established that near Lwala, Uganda,
the late stage of HAT is reached, on average, 4 weeks after
infection with T. b. rhodesiense [29]. Thus presumably, all patients
had experienced several waves of parasitemia, potentially allowing
trypanosome proteins to accumulate in the bloodstream after
secretion or shedding from live parasites or released upon parasite
destruction mediated by the host immune system. In addition, the
identification of trypanosome proteins was facilitated by depletion
of the highly- and moderately-abundant human proteins, the long
reverse phase HPLC peptide fractionation (30 fractions collected
over 80 min) and extensive MS analysis (3 hours of MS time per
fraction for a total instrument time of 90 hours) using a highly
sensitive Q Exactive Orbitrap mass spectrometer. Too much data
were generated in our MS experiments to be described in detail
here, therefore only some of the interesting groups of trypanosome
proteins will be discussed.
To our knowledge, there has been only one previously
published report describing unbiased discovery of proteins from
any pathogen in human body fluids (a single protein identified
with 2 contributing peptides in the saliva of malaria patients [30]),
although targeted assays have been created and used to detect
preselected parasite proteins (from trypanosomes and plasmodia)
in mammalian fluids [9,31]. By using an unbiased discovery
method, it is more likely that those trypanosome proteins which
are abundant, conserved, soluble and persistent in human plasma
will be identified. Our results support this idea.
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Surprisingly, trypanosome VSGs immediately stood out as one
of the most conspicuous groups of proteins identified in the pooled
plasma. It was interesting to find twelve highly divergent
trypanosome VSG sequences (Table 2). The antibody response
of infected hosts is known to be directed against the VSG coat
presented on the dominant antigenic types of trypanosomes of
each parasitemic wave and it has long been believed that within
each wave (at least at early time points in an infection) a single
VSG type dominates. It has often been assumed that the
predominant, abundant and highly immunogenic VSGs would
be cleared from the body rapidly after parasite phagocytosis or
complement mediated lysis. In the plasma sample used here (a
pool from three patients), it would be expected that fewer VSG
types would be seen, perhaps those from the most recent
parasitemic wave. The identification of such a wide variety of
VSGs was unexpected and of interest for understanding the
infection process and our current model of antigenic variation. We
speculate that either the VSGs persist in the bloodstream with
successive parasitemic waves, or the waves of parasitemia become
unsynchronized with parasites expressing multiple different VSG
types late in infection. All the patients used here had late stage
infections so either explanation is possible. Even if our conception
of antigenic variation is compatible with multiple persistent VSGs,
the results indicate that this deep-mining proteomics method is a
powerful tool to obtain a snapshot of the VSG types present in
infected patients and to study the temporal unfolding of the disease
process. We are not aware of any other method that could achieve
this type of analysis. The only other membrane protein confidently
observed in the data set was the kinetoplastid membrane protein
11 (KMP-11, Accession number Tb09.211.4511) that has been
identified in the secretome of T. congolense BSF [32].
The largest groups of annotated trypanosome proteins identified
were those involving protein folding (chaperones and isomerases,
Table 3) and protein degradation (proteases, peptidases and
ubiquitin related proteins, Table 4). This can possibly be explained
by the high rate of cell division and VSG synthesis or recycling in
BSF trypanosomes. Although these proteins have less of a direct
apparent impact on the disease process (compared to the well
known VSGs), the identification of so many of this group (23
chaperones and 18 proteases/ubiquitin related proteins) raises
questions as to why they persist in the bloodstream and whether or
not they play a role in the disease process. Beyond the known
functions of the folding proteins and proteases inside the
trypanosome, it is possible that some (especially the proteases)
have a function once released by the parasites. It is easy to envision
trypanosome derived proteases acting as virulence factors when
released into the bloodstream. Indeed a well-studied trypanosome
protease, congopain, has been hypothesized to act as a virulence
factor [33]. The data that we have generated here may offer
supporting evidence to justify future research into the topic.
In addition to the protein families mentioned above, many
metabolic, cytoskeletal, and signaling proteins of trypanosomes
were identified in human plasma. A further 92 trypanosome
proteins were annotated as uncharacterized ‘‘hypothetical pro-
teins’’, highlighting the understudied nature of these parasite
proteins.
Many of the trypanosome proteins in plasma from HAT
patients are potentially interesting for understanding the biology
and biochemistry of disease. However, the abundant, conserved
proteins are perhaps the most important from an applied point of
view. Identification of trypanosome proteins in plasma may allow
selection of those that might be most useful as biomarkers for
diagnosis and monitoring of African sleeping sickness or animal
trypanosomiasis. A first step might be to determine which are the
most abundant parasite proteins in plasma. However, unlike
several other mass spectrometry techniques such as stable isotope
standards and capture by anti-peptide antibodies (SISCAPA) [34]
or isobaric tags for relative and absolute quantitation (iTRAQ),
that has already been used to study protein expression in
trypanosomes [35], the protein discovery method described here
has no built-in quantitation capability. Therefore, in order to gain
a rough measure of protein abundance, the trypanosome proteins
were assigned a ‘‘molar intensity’’ score which was calculated by
averaging the total ion intensity for a given protein by the number
of peptides identified from that protein. This value represents total
ion intensity per peptide. If it is assumed that a mole of peptide
(regardless of source or chemical nature) gives rise to the same level
of signal intensity, then molar intensity can be used as a means to
rank protein abundance. However, this method is flawed, because
it is known that the mass, charge and physicochemical properties
influence peptide behaviour and thus signal intensity in a mass
spectrometer. Nevertheless, we judge that this method can be used
to rank proteins with an accuracy of approximately one order of
magnitude. We have used this approach to select the 15 most
abundant trypanosome proteins (Table 5). The proteins in this
table, not surprisingly, are conserved soluble proteins and
represent a broad spectrum of functional roles. Six of the fifteen
most abundant trypanosome proteins are chaperones or proteas-
es/ubiquitin related proteins. The rest are a collection of enzymes,
motor proteins, signaling proteins and two proteins of unknown
function (a hypothetical protein and a retrotransposon hot spot
protein). Some of these may be of sufficient abundance to be of
used as biomarkers for diagnosis and monitoring of trypanosome
infections using sandwich immunoassays or other protein detec-
tion techniques. While it is unknown by which route these proteins
entered the human bloodstream (shedding/secretion or lysis/
necrosis), it is interesting to note that six of the abundant proteins
listed in Table 5 (chaperone protein DNAJ, peptidyl prolyl cis-
trans isomerase, triose phosphate isomerase and three forms of
heat shock protein 70) were also identified in the secretome of
cultured T. congolense BSF [32].
To obtain an estimate of their concentrations in plasma, the
molar intensities of the 15 most abundant trypanosome proteins
were compared with the intensities of normal human proteins, also
identified in our experiment, for which literature reported
concentration values are available [19]. Table 6 lists the normal
human proteins (identified in the HAT plasma) that had molar
intensities similar to those from the most abundant trypanosome
proteins. By comparison to the normal human proteins, it appears
that the most abundant trypanosome proteins exist in the
bloodstream in the range of 5–40 mg/mL although again these
are crude approximations from a pooled sample. Nevertheless, this
puts these proteins well within detection range of standard
diagnostic immunoassays and SISCAPA assays [34].
The sample processing and analysis approach developed at the
Broad Institute enabled the confident identification of 4326
distinct human proteins with at least 2 peptides/protein and an
additional 1843 proteins with lower confidence (for a total of 6169
proteins) if single peptide identifications are included. This equates
to approximately 21% of the predicted human proteome [36], or
ca. 30% if single peptide hits are also considered. This represents
one of the largest sets of human plasma proteins reported from a
single MS experiment in the published literature and attests to the
efficacy of the immuno-depletion method coupled with extensive
peptide fractionation and sensitive MS detection.
While some of the trypanosome proteins discovered in plasma
may be useful as biomarkers, their identification here is based on a
single, painstaking, extensive and expensive experiment. Never-
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theless, the unequivocal peptide identification data provide strong
proof of principle for the discovery of parasite proteins in human
body fluids. The next step will be to perform a similar analysis
using plasma from patients with early stage HAT, including those
chronically infected with T. b. gambiense parasites, to identify
proteins that appear early in the infection process and that are
conserved between T. brucei subspecies. In this way, protein
antigens may be identified for development of sandwich immu-
noassays or SISCAPA assays [34] and validation of the biomarkers
for diagnostic utility using plasma or sera from many patients.
To our knowledge, this study reports the first identification of
microbial proteins in the human bloodstream using a unbiased
approach, that is, without the use of an assay designed to
specifically detect predetermined analytes. Previous application of
mass spectrometric approaches to diagnosis of trypanosomiasis
used methods that do not allow identification of the relevant
molecules [37,38].
African trypanosomiasis caused by T. b. rhodesiense may be
ideally suited for the protein discovery methodology described
here because of the high parasite burden experienced by patients
infected with this parasite. In addition, plasma from patients with
late stage infections perhaps contained high levels of trypanosome
proteins since antigenic variation results in sequential and
extended lysis of parasites, leading to a relatively high concentra-
tion of released parasite material. However, our results showing
detection of low abundance proteins imply that the methods
should be effective for biomarker discovery even with infections
showing much lower parasite burdens, for example with T. b.
gambiense. Although infections with African trypanosomes may be
suited to the biomarker discovery method outlined here, the great
sensitivity achieved with the general approach bodes well for
studying the infection proteomics of a variety of infectious diseases.
Supporting Information
Appendix S1 Excel sheet 1 contains a list of all proteins
(trypanosome and human) identified in pooled plasma
from human African trypanosomiasis patients and
listed by number of contributing peptides. Excel sheet 2
shows only the trypanosome proteins discovered in plasma from
patients with human African trypanosomiasis. Excel sheet 3 shows
only the trypanosome proteins (with at least 2 contributing
peptides) organized by putative function.
(XLSX)
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